Ardena’s Nanomedicine Facility secures full GMP approval for manufacturing
Ardena has announced a significant milestone with its state-of-the-art nanomedicine facility at Pivot Park receiving full Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority.
Ardena expands bioanalytical services in Europe
Ardena is strengthening its bioanalytical services with a new laboratory and investments in Europe.
Forbion raises over €2 Billion in new funding for life sciences investments
Are you preparing for your next funding round? Forbion, a leading European life sciences venture capital firm, has announced its largest fundraising to date, raising over €2 billion.
Enhancing drug bioavailability: strategies from Ardena’s experts
Ardena’s Drug Product team has recently published a comprehensive article in Drug Development & Delivery. This technical piece focuses on innovative strategies to tackle solubility and bioavailability challenges in poorly soluble drugs—key hurdles in drug development.
Unveiling the importance of polymorphism in drug development: Insights from Ardena
Ardena shares the latest insights on the critical role of polymorphism in drug development. Learn why early-stage polymorph screens are essential, how they mitigate risks, and the innovative methods Ardena employs to ensure robust drug development.
Press release: Ardena’s Nanomedicines Facility Marks €20 Million Expansion with first GMP approval
Ardena has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility.
Ardena was contracted by Race to manufacture the cGMP RC220 drug product to ensure that it meets the exacting standards required by major global regulatory authorities for human clinical use, including the European Medicines Agency (EMA), the US Food & Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA).
Ardena and ELDICO Scientific announce collaboration agreement
Ardena and ELDICO Scientific have teamed up, granting Ardena access to ELDICO’s cutting-edge electron diffractometer, the ELDICO ED-1.
Ardena and RiboPro Forge Strategic Alliance
Leading contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro to form a new strategic commercial alliance aimed at delivering improvements to the global availability of RNA-based health treatments and address a crucial skills gap in the industry.
or call
Pivot Park – Building RK
Kloosterstraat 9
5349 AB Oss
The Netherlands
+31 (0)412 – 84 60 10
info@pivotpark.com
Pivot Park Exploitatie B.V.
Building OP
Kloosterstraat 9
5349 AB Oss
The Netherlands
10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.
We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.